title: [Home blood pressure monitoring in addition to office blood pressure determination is useful in patients with systolic hypertension before their inclusion into a drug trial].
abstract: OBJECTIVE
  In patients with uncontrolled systolic hypertension, to estimate the value of home blood pressure monitoring in addition to office blood pressure for inclusion in a trial.
  
  
  METHODS
  80 patients with systolic hypertension, defined as SBP > or =140 mmHg and pulse pressure > or =60 mmHg, were treated for 4 weeks with a thiazide diuretic at usual dose (25 mg HCTZ or 1.5 mg indapamide or methyclothiazide 5 mg). Blood pressure was measured using an automatic monitor (Omron M6) at office and at home in the 3 days prior the visit. Subjects with an uncontrolled hypertension were included in the second part of the trial only if there fulfilled inclusion criteria: office SBP > or =140 mmHg and home SBP > or =135 mmHg (mean of 18 measurements obtained on 3 consecutive days) and office pulse pressure > or =60 mmHg.
  
  
  RESULTS
  After 4 weeks with diuretic treatment, 62% of patients fulfilled 3 criteria and were included in the second part of the trial. It was observed 76% of patients with office SBP > or =140 mmHg, 72% with office pulse pressure > or =60 mmHg and 70% with both office SBP and PP criteria. However, only 67% of patients had home SBP > or =135 mmHg. Discrepancy between office and home SBP was observed and subjects with a white coat hypertension was noticed in 14% and masked hypertension in 5%.
  
  
  CONCLUSIONS
  If patients with systolic hypertension have to be included into a drug trial because there are uncontrolled, home blood pressure monitoring in addition to office blood pressure is a very useful criteria for inclusion because misclassifications due to white coat or masked hypertension is frequent in these patients.
authors.affiliation: Service d'endocrinologie-métabolisme, hôpital de la Pitié-Salpêtrière, Paris. xavier.girerd@psl.aphp.fr
authors.forename: X
authors.initials: X
authors.lastname: Girerd
authors.forename: J
authors.initials: J
authors.lastname: Fourcade
authors.forename: J P
authors.initials: JP
authors.lastname: Fauvel
authors.forename: F
authors.initials: F
authors.lastname: Villeneuve
authors.forename: T
authors.initials: T
authors.lastname: Denolle
authors.forename: A
authors.initials: A
authors.lastname: Marquand
authors.forename: C
authors.initials: C
authors.lastname: Dourmap
authors.forename: O
authors.initials: O
authors.lastname: Hanon
mesh_terms: D000368:Aged; D001795:Blood Pressure Determination; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000627:therapeutic use; D008736:Methyclothiazide / Q000627:therapeutic use; D018579:Patient Selection; D013599:Systole
chemical_list: D004232:Diuretics; D007190:Indapamide; D008736:Methyclothiazide